IP Library › Granted Patent US 12,403,095
Granted Patent B2
US 12,403,095 · App. 17/857,442 · Granted Sep 2, 2025

Stabilized tacrolimus composition

Inventors: Nikolaj Skak (Virum, DK); Per Holm (Vanlose, DK)
Assignee: VELOXIS PHARMACEUTICALS, INC.
A61K9/2013A61K9/145A61K9/2077A61K31/436
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,095
App. No.
17/857,442
Granted
Sep 2, 2025
Kind
B2
Abstract

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising e stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Claims (25)

1. A pharmaceutical composition comprising a solid dispersion of tacrolimus in a mixture of a vehicle and a stabilizing agent that is a metal chelating agent and provides a pH below 7 in the composition, wherein

(i) the composition comprises from about 0.5 to about 5% of tacrolimus, based upon 100% total weight of composition,

(ii) the composition contains no more than 0.5% more 8-epitacrolimus after storage at 40° C. at 75% relative humidity for 5 weeks compared to the pharmaceutical composition prior to storage, based upon 100% total weight of tacrolimus, and

(iii) the tacrolimus is the sole active ingredient in the composition, and

(iv) the vehicle does not include a cyclo-dextrin.

2. The composition of claim 1 , wherein the pH in the composition is in the range of 2.5 to 4.0.

3. The composition of claim 1 , wherein the pH in the composition is in the range of 3.0 to 3.6.

4. The composition of claim 1 , wherein the metal chelating agent is an organic acid selected from mono-, di-, oligo- or polycarboxylic acids.

5. The composition of claim 4 , wherein the organic acid is selected from the group consisting of succinic acid, citric acid, tartaric acid, acrylic acid, benzoic acid, malic acid, maleic acid, and sorbic acid.

6. The composition of claim 1 , wherein the stabilizing agent comprises citric acid.

7. The composition of claim 1 , wherein the stabilizing agent comprises tartaric acid.

8. The composition of claim 1 , wherein the vehicle is a mixture of polyethylene glycol and poloxamer.

9. The composition of claim 1 , wherein the composition comprises about 1% tacrolimus, based upon 100% total weight of composition.

10. The composition of claim 1 , wherein a sufficient amount of the stabilizing agent is present in the composition such that the composition comprises less than 0.5% by weight of 8-epitacrolimus after 12 weeks of storage at 25° C. and 60% relative humidity, based upon 100% total weight of tacrolimus.

11. A pharmaceutical composition comprising a solid dispersion of tacrolimus in a mixture of a vehicle and a stabilizing agent that is a metal chelating agent and provides a pH below 7 in the composition, wherein (i) the composition comprises from about 0.5 to about 5% of tacrolimus, based upon 100% total weight of composition, (ii) the composition contains no more than 0.2% more 8-epitacrolimus after storage at 25° C. at 60% relative humidity for 5 weeks compared to the pharmaceutical composition prior to storage, based upon 100% total weight of tacrolimus, (iii) the tacrolimus is the sole active ingredient in the composition, and (iv) the vehicle does not include a cyclo-dextrin.

12. The composition of claim 11 , wherein the pH in the composition is in the range of 2.5 to 4.0.

13. The composition of claim 11 , wherein the pH in the composition is in the range of 3.0 to 3.6.

14. The composition of claim 11 , wherein the metal chelating agent is an organic acid selected from mono-, di-, oligo- or polycarboxylic acids.

15. The composition of claim 14 , wherein the organic acid is selected from the group consisting of succinic acid, citric acid, tartaric acid, acrylic acid, benzoic acid, malic acid, maleic acid, and sorbic acid.

16. The composition of claim 11 , wherein the stabilizing agent comprises citric acid.

17. The composition of claim 11 , wherein the stabilizing agent comprises tartaric acid.

18. The composition of claim 11 , wherein the vehicle is a mixture of polyethylene glycol and poloxamer.

19. The composition of claim 11 , wherein the composition comprises about 1% tacrolimus, based upon 100% total weight of composition.

20. The composition of claim 11 , wherein a sufficient amount of the stabilizing agent is present in the composition such that the composition comprises less than 0.5% by weight of 8-epitacrolimus after 12 weeks of storage at 25° C. and 60% relative humidity, based upon 100% total weight of tacrolimus.

21. The composition of claim 1 , wherein the composition is in the form of a tablet.

Assignments (1)
CHANGE OF ADDRESS Recorded Jun 7, 2024
From: VELOXIS PHARMACEUTICALS INC.
To: VELOXIS PHARMACEUTICALS INC.
Reel/Frame 067666/0352 →
Priority Claims (1)
DK DK2010-00137 · Feb 17, 2010 · national
Continuity (8)
Continuation 16188805 · Nov 13, 2018
Continuation 15405879 · Jan 13, 2017
Continuation 13029304 · Feb 17, 2011
Continuation In Part 12499034 · Jul 7, 2009
Continuation In Part PCTDK2008050130 · May 30, 2008
Provisional Application 61305941 · Feb 18, 2010
Provisional Application 61079015 · Jul 8, 2008
Related Publication 20230101012A1 · Mar 30, 2023
References Cited (81)
US 4716153A · Morishita et al. · 1987 [cited by applicant]
US 5601844A · Kagayama et al. · 1997 [cited by applicant]
US 5962022A · Bolt et al. · 1999 [cited by applicant]
US 6168806B1 · Lee et al. · 2001 [cited by applicant]
US 6204243B1 · Posanski · 2001 [cited by applicant]
US 6346537B1 · Hata et al. · 2002 [cited by applicant]
US 6372760B1 · Kato et al. · 2002 [cited by applicant]
US 6387918B1 · Yamanaka et al. · 2002 [cited by applicant]
US 6440458B1 · Yamashita et al. · 2002 [cited by applicant]
US 6503883B1 · Posanski · 2003 [cited by applicant]
US 6576259B2 · Yamashita et al. · 2003 [cited by applicant]
US 6761895B2 · Sawada et al. · 2004 [cited by applicant]
US 6884433B2 · Yamashita et al. · 2005 [cited by applicant]
US 6884436B2 · Kipp et al. · 2005 [cited by applicant]
US 7994214B2 · Holm · 2011 [cited by examiner]
US 8685998B2 · Gordon et al. · 2014 [cited by applicant]
US 20020028240A1 · Sawada et al. · 2002 [cited by applicant]
US 20030180352A1 · Patel et al. · 2003 [cited by applicant]
US 20050169993A1 · Yamashita et al. · 2005 [cited by applicant]
US 20050249799A1 · Jacob et al. · 2005 [cited by applicant]
US 20060045865A1 · Jacob et al. · 2006 [cited by applicant]
US 20060154953A1 · Keri et al. · 2006 [cited by applicant]
US 20060159766A1 · Jenkins et al. · 2006 [cited by applicant]
US 20060177500A1 · Shin et al. · 2006 [cited by applicant]
US 20060210638A1 · Liversidge et al. · 2006 [cited by applicant]
US 20060287352A1 · Holm et al. · 2006 [cited by applicant]
US 20070122482A1 · Holm et al. · 2007 [cited by applicant]
US 20080153866A1 · Woo · 2008 [cited by examiner]
US 20080181947A1 · Kojima · 2008 [cited by applicant]
US 20090011013A1 · Ranklove et al. · 2009 [cited by applicant]
US 20090011018A1 · Kondo et al. · 2009 [cited by applicant]
US 20100008984A1 · Holm et al. · 2010 [cited by applicant]
US 20100105717A1 · Gordon et al. · 2010 [cited by applicant]
EP 0184162A2 · 1986 [cited by applicant]
EP 0444659A2 · 1991 [cited by applicant]
EP 1064942A1 · 2001 [cited by applicant]
EP 1275373A1 · 2003 [cited by applicant]
EP 1275381A1 · 2003 [cited by applicant]
JP 62277321A · 1987 [cited by applicant]
JP 02295919 · 1990 [cited by applicant]
JP 200837808 · 2008 [cited by applicant]
KR 20070014872A · 2007 [cited by applicant]
WO WO9323022A1 · 1993 [cited by applicant]
WO WO9824418A1 · 1998 [cited by applicant]
WO WO9949863A1 · 1999 [cited by applicant]
WO WO0137808 · 2001 [cited by applicant]
WO WO01074359A1 · 2001 [cited by applicant]
WO WO0195939A1 · 2001 [cited by applicant]
WO WO03004001A1 · 2003 [cited by applicant]
WO WO2005004848A1 · 2005 [cited by applicant]
WO WO2005020993A1 · 2005 [cited by examiner]
WO WO2005087195A2 · 2005 [cited by applicant]
WO WO2006062334A1 · 2006 [cited by applicant]
WO WO2006083130A1 · 2006 [cited by examiner]
WO WO2006136175A2 · 2006 [cited by applicant]
Prajapati et al (International Journal of Pharmaceutics, Aug. 2020, vol. 586, pp. 1-9) (Year: 2020). [cited by examiner]
Yadav et al (International Journal of Science and Research Archive, 2023, vol. 09, pp. 474-485) (Year: 2023). [cited by examiner]
Overhoff et al (Pharmaceutical Research, Jan. 2008, vol. 25, pp. 167-175) (Year: 2008). [cited by examiner]
Skytte et al (J Nat Prod, 2010, vol. 73, pp. 776-779) (Year: 2010). [cited by examiner]
Honbo et al., 1987, The oral dosage form of Fk-506, Transplantation Proceedings, vol. 19, No. 5, supplement 6, pp. 17-22. [cited by applicant]
Nishi et al., 2004, The Expression of Intestinal CYP3A4 in the Piglet Model, Transplantation Proceedings, vol. 36, No. 2, pp. 361-363. [cited by applicant]
Nishi, et al., 2004, The Colon Displays an Absorptive Capacity of Tacrolimus, Transplantation Proceedings, vol. 36, No. 2, pp. 364-366. [cited by applicant]
Sano et al., 2002, Oral FK 506 blood levels are elevated in pig short bowl model: Further investigations with co-administration of an intestinal CYP3A4 inhibitor, Transplantation Proceedings vol. 34, No. 3, pp. 1050-105… [cited by applicant]
Tacrolimus (Systemic) Drugs.com, Drug Information Online; http://www.drugs.com/mmx/tacrolimus.hmtl; pp. 1-43; Printed on Oct. 5, 2009. [cited by applicant]
U.S. Appl. No. 13/167,095, filed Jun. 23, 2011. [cited by applicant]
U.S. Appl. No. 13/167,160, filed Jun. 23, 2011. [cited by applicant]
U.S. Appl. No. 13/167,281, filed Jun. 23, 2011. [cited by applicant]
U.S. Appl. No. 13/167,334, filed Jun. 23, 2011. [cited by applicant]
U.S. Appl. No. 13/167,420, filed Jun. 23, 2011. [cited by applicant]
Kjaergaard, et al., Priling—Multiple Core Encapsulation, http://www.niroinic.com/food_Chemical/prilling_encapsulation.asp. [cited by applicant]
Yang, et al., Int. J. Pharmaceuticals, 1992, vol. 86(2-3), p. 247-257; Abstract only p. 1 of 1. [cited by applicant]
U.S. Appl. No. 13/167,381, filed Jun. 23, 2011. [cited by applicant]
U.S. Appl. No. 13/178,280, filed Jul. 7, 2011. [cited by applicant]
Aqion, pH of Organic Acids, 2012-2017, last modified Apr. 20, 2016 (Year: 2016). [cited by applicant]
Akashi, et al., (Journal of Pharmaceutical and Biomedical Analysis, 1996, vol. 14, pp. 339-346). [cited by applicant]
European Medicines Agency (EMA) (Assessment Report for Modigraf—International Nonproprietary Name: Tacrolimus, 2009, p. 1-30). [cited by applicant]
Formulation in Pharmacy Practice, 2nd edition (Tacrolimus, Aug. 21, 2004 on Wayback Machine). [cited by applicant]
Chromatography Online, downloaded Oct. 2018; http://www.chromatography-online.org/quant/Chromatographic%20Data/Data%20Processing/Peak%20Area%20Measurements.php (Year 2018). [cited by applicant]
Aqion, pH of Organic Acids, 2012-2014. [cited by applicant]
Bolt et al., JP 02295919 A, Derwent English abstract, Dec. 1990. [cited by applicant]
Skytte et al (J Natl Prod, Feb. 18, 2010, vol. 73, pp. 776-779 (year: 2010). [cited by applicant]